CLINICAL TRIALS PROFILE FOR RUFINAMIDE
✉ Email this page to a colleague
All Clinical Trials for RUFINAMIDE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00334958 ↗ | Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures | Completed | Eisai Inc. | Phase 3 | 2006-02-13 | To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic drugs (AEDs). |
NCT00448539 ↗ | Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures | Terminated | Eisai Inc. | Phase 3 | 2007-03-15 | This was an open-label extension study in adolescent and adult (between 12 and 80 years old) participants who had completed their participation in Study E2080-A001-301. The main objective of this study was to evaluate the safety and efficacy of long-term administration of rufinamide for the control of epileptic seizures in participants who had refractory partial seizures despite treatment with a maximum of three approved antiepileptic drugs (AEDs). |
NCT00595231 ↗ | Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD) | Completed | INC Research | Phase 2 | 2008-03-01 | A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder. |
NCT00595231 ↗ | Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD) | Completed | Syneos Health | Phase 2 | 2008-03-01 | A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder. |
NCT00595231 ↗ | Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD) | Completed | Biotie Therapies Inc. | Phase 2 | 2008-03-01 | A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder. |
NCT01146951 ↗ | A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304) | Completed | Eisai Limited | Phase 3 | 2010-06-01 | To confirm that the combination therapy of rufinamide has superior efficacy compared to placebo in patients with Lennox-Gastaut syndrome. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RUFINAMIDE
Condition Name
Clinical Trial Locations for RUFINAMIDE
Trials by Country
Clinical Trial Progress for RUFINAMIDE
Clinical Trial Phase
Clinical Trial Sponsors for RUFINAMIDE
Sponsor Name